Development of vaccines against Zika virus.

Abstract

Zika virus is an emerging pathogen of substantial public health concern to human beings. Although most infections are asymptomatic or present with benign, self-limited symptoms, a small percentage of patients have complications, such as congenital anomalies in the developing fetus of pregnant women infected with the virus and neurological complications (eg, Guillain-Barré syndrome). To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection. In this Review, we examine vaccine development efforts for Zika virus to date and research gaps in the development of candidate vaccines against Zika virus. Top research priorities should include development of a better understanding of immunity to Zika virus to establish clear correlates of protection; determination of what effect, if any, Zika vaccine-induced immune responses will have on subsequent dengue virus infection; evaluation of vaccine immunogenicity and efficacy in healthy adults and in the various subpopulations affected by Zika virus infection (children, pregnant women, women of childbearing age, and eldery people); and identification of the molecular mechanisms that underlie birth defects and neurological sequelae related to Zika virus.

• Authors: Gregory A Poland, Richard B Kennedy, Inna G Ovsyannikova, Ricardo Palacios, Paulo Lee Ho, Jorge Kalil
• Journal: The Lancet. Infectious diseases (Lancet Infect Dis) Vol. 18 Issue 7 Pg. e211-e219 (07 2018) ISSN: 1474-4457 [Electronic] United States
• PMID: 29396004 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2018 Elsevier Ltd. All rights reserved.

Chemical References

• Antibodies, Viral
• Viral Vaccines

Topics

• Antibodies, Viral (analysis)
• Dengue Virus (drug effects)
• Drug Development
• Guillain-Barre Syndrome (diagnosis, virology)
• Humans
• Viral Vaccines (therapeutic use)
• Zika Virus Infection (drug therapy, prevention & control)